Zobrazeno 1 - 10
of 1 395
pro vyhledávání: '"E. Holler"'
Autor:
S. dertschnig, J. finke, D. heim, U. schanz, E. holler, U. holtick, G. socié, T. teshima, C. bucher, J. passweg
Publikováno v:
HemaSphere, Vol 6, Pp 136-137 (2022)
Externí odkaz:
https://doaj.org/article/18191fa55fdd48279be1987da513a4f2
Publikováno v:
International Journal of Inflammation, Vol 2010 (2010)
Graft-versus-Host Disease (GvHD) is the most serious complication of allogeneic stem cell transplantation (SCT) and results from an activation of donor lymphocytes by recipient antigen-presenting cells (APCs). For a long time, it has been postulated
Externí odkaz:
https://doaj.org/article/71e72c05b9134d00baa162a799cde56c
Autor:
Vismaya S Bachu, Heba Mahjoub, Albert E Holler, Tudor Crihalmeanu, Dheevena M Bachu, Varun Ayyaswami, Pearman D Parker, Arpan V Prabhu
Publikováno v:
JMIR Formative Research, Vol 6, Iss 2, p e32443 (2022)
BackgroundThe COVID-19 pandemic spurred an increase in online information regarding disease spread and symptomatology. ObjectiveOur purpose is to systematically assess the quality and readability of articles resulting from frequently Google-searched
Externí odkaz:
https://doaj.org/article/edd02bef28824e539d88701997785b48
Publikováno v:
Journal of Clinical and Translational Science, Vol 6, Pp 2-2 (2022)
OBJECTIVES/GOALS: Prostate cancer is the 2nd most common cancer among men. 1/3 of these men have a slow-growing disease that can be managed without intervention. Instead of treatment, they can enter an active surveillance program. The goal of this st
Externí odkaz:
https://doaj.org/article/667406776d394a718ca3521f67528919
Autor:
Karen L. Smith, Carolyn Mead-Harvey, Gina L. Mazza, Albert E. Holler, Eileen Shinn, Elizabeth Frank, Michelle Melisko, Cyd Eaton, Jeannine M. Salamone, Teri Pollastro, Patricia Spears, Antonio C. Wolff, Gabrielle B. Rocque
Publikováno v:
Cancer Research. 83:P6-08
Background: Historically, less than 10% of adult patients with cancer enroll in clinical trials, however, enrollment dropped further at the onset of the COVID-19 pandemic. Barriers to trial participation during the pandemic have not been reported. As
Inhibitors of the bromodomain and extra-terminal domain (BET) family proteins modulate EWS-FLI1 activities in Ewing sarcoma. However, the efficacy of BET inhibitors as a monotherapy was moderate and transient in preclinical models. The objective of t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d658e66291004705abdb4c5bbbf8a671
https://doi.org/10.1158/1535-7163.c.6538012.v1
https://doi.org/10.1158/1535-7163.c.6538012.v1
Figure S1. Expression of Myr-AKT1 in TC32 and TC71 cells. Figure S2. The blockade of IGF1R sensitizes Ewing sarcoma cells to BET inhibitors. Figure S3. Dose-dependent response to the combination of BET inhibitors and IGF1R inhibitors in Ewing sarcoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09302556e6550787b6c20e2245b66823
https://doi.org/10.1158/1535-7163.22505257
https://doi.org/10.1158/1535-7163.22505257
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Jacob E. Berchuck, Catherine Handy Marshall, Nabil Adra, Fadi Taza, Emmanuel S. Antonarakis, Hao Wang, Oren Smaletz, Wei Fu, Rahul Aggarwal, Albert E Holler, Neeraj Agarwal, Pedro C. Barata, Nellie Nafissi, Alexandra O. Sokolova, Adam Kessel, Panagiotis J. Vlachostergios, Christopher Su, Cora N. Sternberg, Ajjai Alva, Heather H. Cheng, Ryan Ashkar, Alan H. Bryce, Costantine Albany, Mary-Ellen Taplin, A. Oliver Sartor, Diogo Assed Bastos
Publikováno v:
JCO Precision Oncology. :1200-1220
PURPOSE Two poly (ADP-ribose) polymerase (PARP) inhibitors (olaparib and rucaparib) are US Food and Drug Administration–approved for patients with metastatic castration-resistant prostate cancer (mCRPC) harboring BRCA1/ 2 mutations, but the relativ